Objectives of Treatment GOLD 2018 Pharmacologic Treatment Recommendations GOLD 2018 Pharmacologic Treatment Recommendations c ont GOLD 2018 Pharmacologic Treatment Recommendations in Groups C and D ID: 738802
Download Presentation The PPT/PDF document "When Would You Use Single Inhaler Triple..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
When Would You Use Single Inhaler Triple Therapy in COPD?Slide2
Objectives of TreatmentSlide3Slide4Slide5Slide6
Anti-Inflammatory Therapy in Stable COPDSlide7
WISDOM: Exacerbation Risk in Patients With Prior Exacerbations and Elevated Blood EosinophilsSlide8
Blood Eosinophils and Prediction of ICS EffectsSlide9
Anti-Inflammatory Therapy in Stable COPDSlide10
Associated MeasuresSlide11
Associated Measures (cont)Slide12
Individualized Benefit-Risk AssessmentSlide13
Triple Inhaled TherapySlide14Slide15
Advantages of a Single Inhaler TherapySlide16Slide17
IMPACT: Incidence of PneumoniaSlide18
LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA in the IMPACT TrialSlide19
LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE TrialSlide20
LABA/LAMA/ICS vs LABA/LAMA in the TRIBUTE Trial (cont)Slide21
Main Adverse Events in the TRIBUTE TrialSlide22
Advantages of a Single Inhaler TherapySlide23
Adherence to Inhaled Therapy and MortalitySlide24Slide25
ConclusionSlide26
AbbreviationsSlide27
Abbreviations (cont)